Northwest & Ethical Investments L.P. Sells 756 Shares of Danaher Co. (NYSE:DHR)

Northwest & Ethical Investments L.P. lowered its position in shares of Danaher Co. (NYSE:DHR) by 17.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,611 shares of the conglomerate’s stock after selling 756 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Danaher were worth $1,004,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the third quarter worth about $40,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the second quarter worth approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.4 %

Shares of DHR stock opened at $239.84 on Friday. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The company has a 50-day simple moving average of $254.59 and a two-hundred day simple moving average of $259.44. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $173.23 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.39 and a beta of 0.85.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Raymond James cut their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. StockNews.com upgraded Danaher from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.